ASLAN Pharmaceuticals Ltd(NASDAQ:ASLN) stock News

ASLN Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Benzinga - Mentions: ONVO CERO

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

a year ago - By: Benzinga - Mentions: AEHR FIVE SYF SAVA ...

Dow Jumps 200 Points; Synchrony Financial Posts Upbeat Earnings

a year ago - By: InvestorPlace

ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024

a year ago - By: BusinessInsider

ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation

2 years ago - By: BusinessInsider

ASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal

a year ago - By: InvestorPlace - Mentions: SMX TPST RELI NXL ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab

a year ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference

1 years ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

1 years ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

1 years ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice

1 years ago - By: ASLAN PHARMACEUTICALS LIMITED

ASLAN Pharmaceuticals Ltd (ASLN) Stock News

ASLN Latest News, Press Relases and Analysis